[1] GUO L, HU T S, HU Y M, et al．6-Bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis
B virus infection: US, 20140343032A1 [P]．2014-11-20．
[2] QIU Z, LIN X, ZHANG W, et al．Discovery and pre-clinical characterization of third-generation 4-H
heteroaryldihydropyrimidine (HAP) analogues as hepatitis B virus (HBV) capsid inhibitors [J]．J Med Chem, 2017,60(8): 3352-3371．
[3] WU G L, KOU B Y, TANG G Z, et al．Synthesis of novel and conformationally constrained bridged amino acids as compact modules for drug discovery [J]．Tetrahedron Lett,2016, 57: 599-602．
[4] KARAKI F, KABASAWA Y, YANAGIMOTO T, et al.Visible-light-triggered release of nitric oxide from N-pyramidal nitrosamines [J]．Chemistry, 2012, 18(4):1127-1141．
[5] KUBYSHKIN V S, MIKHAILIUK P K, KOMAROV I V．Synthesis of 7-azabicyclo[2.2.1]heptane-1,4-dicarboxylic acid, a rigid non-chiral analogue of 2-aminoadipic acid [J]．Tetrahedron Lett, 2007, 48(23): 4061-4063．
[6] GOLDSPINK N J, SIMPKINS N S, BECKMANN M．Highly enantioselective synthesis of substituted piperidines using the chiral lithium amide base approach [J]．Synlett,1999, (8): 1292-1294．